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Abstract
We report two unrelated patients with infantile onset leukoencephalopathy with
vanishing white matter (VWM) and hyperinsulinaemic hypoglycaemia. To our
knowledge, this association has not been described previously. Both patients had com-
pound heterozygous pathogenic variants in EIF2B4 detected on exome sequencing and
absence of other variants which might explain the hyperinsulinism. Hypoglycaemia
became apparent at 6 and 8 months, respectively, although in one patient, transient neo-
natal hypoglycaemia was also documented. One patient responded to diazoxide and the
other was managed with continuous nasogastric feeding. We hypothesise that the patho-
physiology of hyperinsulinism in VWM may involve dysregulation of transcription of
genes related to insulin secretion.
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1 | INTRODUCTION
Vanishing white matter (VWM, OMIM 603896) is also
known as childhood ataxia with central nervous system
hypomyelination (CACH), and is one of the most com-
mon leukodystrophies.1 VWM encompasses a spectrum
of clinical disease, with the most severe form having early
infantile or even prenatal onset, and the least severe form
being characterised by adult onset and slow progression, with
ovarian dysgenesis.2 Age of onset is most frequently in early
childhood, with prominent cerebellar ataxia and spasticity.
Cognitive deterioration, epilepsy and optic atrophy can occur
as the disease progresses.3-5 Rapid neurological deterioration
can be triggered by stresses such as febrile infection, minor
head trauma, and even acute fright.3,5-8
Diagnosis of VWM is based on characteristic MRI abnor-
malities.2 Pathogenic variants in one of five genes (EIF2B1,
EIF2B2, EIF2B3, EIF2B4, EIF2B5) encoding the five sub-
units of the eukaryotic translation initiation factor 2B (eIF2B)
are found in ~90% of individuals with VWM.9 Characteristic
MRI findings include diffuse, symmetric cerebral white matter
involvement, with low T1, proton density, and FLAIR images
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and high signal on T2 images. There is relative sparing of
U-fibres, internal capsules, anterior commissure and the outer
rim of the corpus callosum.2,9 These abnormalities can be pre-
sent in presymptomatic individuals.5,7,10,11 Over time, there is
progressive rarefaction and cystic degeneration of the affected
white matter, which is eventually replaced by CSF-like fluid.5,7
The cerebellar white matter and brainstem may also be
involved, but with atrophy rather than cystic degeneration.5,7
2 | METHOD
Patients 1 and 2 were assessed by the Royal Children's Hospital
Metabolic and Neurology services. DNA was extracted from
whole blood from both patients and exome sequencing performed
using the Nextera Rapid Capture Exome kit (Illumina). Sequenc-
ing was performed on an Illumina HiSeq4000. Data was
processed using Cpipe.12 Curation of variants was phenotype-
driven with relevant gene lists used for variant prioritisation.
Classification of variants was based onACMGguidelines.13
3 | PATIENT 1
This patient is the second child born to healthy non-
consanguineous parents. He was born at 36 weeks and
5 days by emergency caesarean section due to decreased
fetal movements and amniotic fluid index. This occurred
in the setting of gestational diabetes and decreasing mater-
nal insulin requirements suggestive of placental insuffi-
ciency. Delivery was uncomplicated and Apgars were 9 at
1 and 5 minutes. Respiratory distress developed on day
1 with a small pneumothorax noted. Surfactant was given
and CPAP was delivered for 2 days. Hypoglycaemia did
not occur in the neonatal period.
The infant's early motor development was mildly delayed,
unilateral sensorineural hearing loss was noted, and cows'
milk protein allergy was diagnosed. At age 6 months, he pres-
ented with status epilepticus in the context of hypoglycaemia
(1.8 mmol/L measured by dextrometer) although the subse-
quent formal glucose level was 2.9 mmol/L and the insulin
level was 5mIU/L. This occurred on a background of 5 days
of poor feeding, lethargy, developmental regression with
FIGURE 1 Top row is patient 1 (age 6 months) and bottom row is patient 2 (age 9 months). The images in the two left columns are axial
T2-weighted at 1.5 T showing a diffuse leukoencephalopathy with symmetric high signal throughout the cerebral and cerebellar white matter. There
is relative sparing of the internal capsules. The images in the right column are FLAIR sequences showing rarefaction of the white matter (arrows)
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hypotonia and focal seizures characterised by right sided
facial and upper limb clonic jerking. He was commenced on
maintenance levetiracetam. A further hypoglycaemic episode
was recorded in hospital with a blood glucose level of
1.9 mmol/L, less than 2.5 hours after a nasogastric bolus feed.
This occurred in the context of a mild bronchiolitic illness
and single vomit several hours prior to the documented
hypoglycaemia. Critical samples including insulin level, free
fatty acids, and β hydroxybutyrate were not obtained at the
time of hypoglycaemia, but urine organic acids and
acylcarnitine profile were normal, without evidence of ketosis.
MRI brain performed at 6 months of age showed mar-
ked T2 hyperintensity in the supra- and infra-tentorial
white matter with extensive diffusion restriction.
(Figure 1) The possibility of Aicardi-Goutieres syndrome
was raised due to the MRI appearance but CT brain did
not show calcifications and CSF neopterin was not ele-
vated. Extensive metabolic workup including paired
blood and CSF samples was unrevealing. Chromosome
microarray was normal.
Hypoglycaemia was an ongoing but intermittent problem,
with fasting times of less than 4 hours. Seizures continued to
occur infrequently on levetiracetam monotherapy. There was
slow developmental progress, including improved head
control and the ability to sit briefly unsupported by age
9 months. He had a gastrointestinal illness aged 10 months
without developmental regression, but with recurrent
hypoglycaemia which persisted after resolution of the ill-
ness. Continuous nasogastric feeding was instituted, and
attempts to reinstate a bolus regimen were unsuccessful due
to recurrence of hypoglycaemia. At 12 months, he was admit-
ted for investigation and management of the ongoing hyp-
oglycaemic episodes. Hyperinsulinism was noted, with
several instances of inadequate suppression of insulin in
the context of hypoglycaemia. In one episode, glucose
was 2.3 mmol/L and insulin 5 mIU/L. Cortisol and growth
hormone levels were normal. Hypoglycaemia occurred
despite glucose delivery rate (GDR) of 9 mg/kg/min via con-
tinuous nasogastric feed. Hypoglycaemia resolved after
diazoxide was commenced at 8 mg/kg/d and weaned to
5 mg/kg/d later.
Unfortunately, during this admission he developed a
Parainfluenza 3 related lower respiratory tract infection.
Rapid neurological deterioration ensued, necessitating intu-
bation and ventilation. A repeat MRI showed progression of
the white matter abnormality, with rarefaction of affected
white matter and atrophy of the brainstem and cerebellum,
suggesting a diagnosis of VWM. There was abnormal sig-
nal in the basal ganglia and cerebellum, and restricted dif-
fusion of the cerebellum and subcortical U fibres. After
1.5 weeks without improvement, and a failed extubation
attempt, he became bradypnoeic with irregular respiration.
Death occurred soon after extubation. Muscle, liver and
skin biopsies were taken for respiratory chain enzymology,
and were stored pending genetic studies.
3.1 | Exome sequencing results
Exome sequencing detected compound heterozygous mis-
sense variants in the EIF2B4 gene: a paternally inherited
c.725C>T (p.Pro242Leu) variant and a maternally inherited
c.1301T>C (p.Leu434Pro) variant. The c.725C>T variant
results in a moderate amino acid change at a highly conserved
residue within the IF-2B domain. It has been previously
described in four homozygous patients with EIF2B4-related leu-
kodystrophy.14 The c. 1301 T>C variant results in a moderate
amino acid change at a highly conserved residue located within
the IF-2B domain and is absent from population databases
(gnomAD, dbSNP, 1000G). In silico predictions for this variant
are consistently pathogenic (Polyphen, SIFT, CADD, Mutation
Taster). No pathogenic changes were detected to explain the
hyperinsulinism, with the following genes being analysed:
ABCC8, AKT2, GCK, GLUD1, HADH, HNF1A, HNF4A,
INS, INSR, KCNJ11, MPI, PDX1, SLC16A1, USHIC, UCP2.
Adequate coverage of these genes was observed, with a mean of
91% of bases sequenced at greater than ×20.
4 | PATIENT 2
Patient 2 was born at term, to healthy nonconsanguineous
parents whose only previous pregnancy had ended in
unexplained stillbirth. He had apnoeas and hypoglycaemia on
day 3 of life and was given antibiotic cover for suspected sep-
sis. Hypoglycaemia persisted, with intravenous dextrose being
given for 11 days, and the cause being attributed to a difficult
delivery and possibly infection. Urine metabolic screen and
organic acids were normal and plasma amino acids were non-
diagnostic. Newborn screening was normal. A microarray
was performed because of subtle dysmorphism and the result
was normal. By 5 months of age, there were concerns with
recurrent vomiting, slow development and lethargy. Mild
developmental regression was noticed over the following
months. At 8 months of age, he was admitted to the hospital
due to failure to thrive and accelerated regression of motor
skills over the preceding 3 weeks. He lost the ability to roll, a
motor skill previously gained at 5 months. He could sit briefly
unassisted in a tripod position. He had axial and appendicular
hypotonia with poor head control.
Recurrent hypoglycaemia was noted in hospital, despite
3 hourly bolus feeds with GDR of 6.2 mg/kg/min. On one
occasion, glucose was 1.9 mmol/L and insulin was 2.1 mU/L.-
Guthrie card acylcarnitines were normal several hours later.
He was asymptomatic during the hypoglycaemic episodes.
There were difficulties in obtaining a full hypoglycaemia
screen, and additional insulin levels were not obtained at
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the time of hypoglycaemia. However, ketones were low
when tested during hypoglycaemic episodes consistent
with hyperinsulinism. Continuous nasogastric feeds were
instituted with a GDR of ~9 mg/kg/min, with resolution of
the hypoglycaemia.
Extensive biochemical investigations on blood and CSF
were unrevealing. A trial of thiamine, riboflavin and CoQ10
was commenced, but was limited by vomiting. Brain MRI at
9 months was suggestive of a leukodystrophy, with confluent
cerebral and cerebellar white matter signal changes, with lesser
degree of involvement of the corpus callosum, internal capsule
and brainstem, with patchy globus pallidi signal change. The
pattern was suggestive of myelin destruction. (Figure 1).
Neurological deterioration occurred rapidly, with sei-
zures, increased peripheral tone and apnoeas. He died at age
10 months.
4.1 | Exome sequencing results
Exome sequencing detected compound heterozygous missense
variants in the EIF2B4 gene. A maternally inherited variant,
c.725C>T (p.Pro242Leu) and a paternally inherited variant,
c.628G>T (p.Gly210Cys) were identified. The first variant was
the same recurrently reported variant found in Patient 1. The
second c.628G>T variant results in a major amino acid change
at a highly conserved residue and is absent from population
databases (gnomAD, dbSNP, 1000G). In silico predictions con-
sistently report this variant to be pathogenic (Polyphen, SIFT,
CADD, Mutation Taster).
5 | DISCUSSION
Disease mechanisms in VWM are incompletely understood.
eIF2B is an evolutionarily conserved protein complex
involved in translation initiation.15-17 The eIF2B-catalysed
step of GDP/GTP exchange is rate-limiting in translation initi-
ation, regulating the rate of global protein synthesis.15 eIF2B
activity is regulated by numerous factors, including phosphor-
ylation of the eIF2α subunit, which inhibits mRNA translation
by acting as a competitive inhibitor of eIF2B.18 During cellu-
lar stress, a mechanism known as the unfolded protein
response (UPR) is activated to inhibit protein synthesis and
promote the degradation of unfolded or denatured pro-
teins.19-21 Cellular stresses lead to eIF2α phosphorylation,
inhibition of eIF2B and translation inhibition.22-24 As neuro-
logical deterioration is often triggered by stress in VWM
patients, it has been hypothesised that the UPR drives the
pathophysiology.2 While decreased eIF2B activity does not
appear to affect the global rate of protein synthesis or cellular
survival and proliferation in VWM patients,25-28 evidence of
activation of the UPR has been found in the white matter of
VWM patients in vivo, and in cells with VWM mutations
in vitro.27-30 In VWM patients, the UPR appears to be acti-
vated in white matter astrocytes and oligodendrocytes, while
other tissues with a high rate of protein synthesis may not be
affected.27,28 Recently, it has been observed that VWM cells
hyper-repress translation during stress conditions, and there is
disruption of a negative feedback loop which allows stress
adaptation and translational recovery in healthy cells (Moon
and Parker, 2018).31
Insulin secretion is complex, and synthesis is regulated at
both the transcription and translation levels. The speed of pro-
tein translation in pancreatic β cells is increased in response to
nutrients. This process is partly controlled by dephosphoryla-
tion of eIF2a.32 Insulin rapidly activates protein synthesis via
mechanisms including activation of protein kinase B which
phosphorylates and inactivates glycogen synthase kinase
3, which leads to the dephosphorylation of eIF2B, contribut-
ing to overall activation of protein synthesis.33
VWM can involve multiple systems, with ovarian dysgene-
sis being frequently reported, and in severe early onset cases,
growth retardation, pancreatitis, renal hypoplasia, hepato-
splenomegaly, and cataracts have been reported.34 The previ-
ously reported pancreatic involvement is intriguing in this
context, but difficult to relate pathophysiologically to hyperin-
sulinism, as opposed to exocrine and endocrine insufficiency.
While it is unknown how eIF2b mutations might affect
glycaemic control, intriguingly, the alpha subunit of eIF2B
has been noted to associate with adrenergic receptors.35 In
addition, endoplasmic reticulum stress signals, such as phos-
phorylation of PERK and eIF2a, have been induced by treat-
ment of PC12 cells with noradrenaline.36 This raises the
possibility of the acute fright and other stress responses seen
in VWM being triggered by adrenaline or noradrenaline.
None of the currently identified genes associated with hyper-
insulinism encode proteins involved with adrenaline, nor-
adrenaline or other counter-regulatory hormones, however, a
genetic cause is not identified in around 40% of cases of
hyperinsulinism.37,38
To our knowledge, hyperinsulinism has not previously
been reported in VWM. A second pathology seems unlikely
in nonconsanguineous families where exome testing did not
reveal a cause of hyperinsulinism, however a relationship
between hyperinsulinism and VWM is neither confirmed
nor readily explained with current knowledge of the patho-
physiology. We suggest the most likely pathogenic mecha-
nism involves alteration of gene expression in genes
involved in insulin regulation, potentially related to altered
eIF2B activity in pancreatic beta cells.
6 | CONCLUSION
We report two cases of hyperinsulinaemic hypoglycaemia in
children with VWM disease associated with EIF2B4
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mutations, a phenomenon not previously reported. The
mechanism by which EIF2B mutations may cause hyperin-
sulinism is not clear, but we hypothesise that it may be via
the role of eIF2B's in translation initiation and regulation. It
also remains to be seen whether there is a genotype/pheno-
type relationship, should the association be confirmed. In
our patients, the hypoglycaemia was a significant manage-
ment challenge, responding to continuous feeds at high
GDRs or diazoxide. Clinicians should be alert to the possi-
bility of hypoglycaemia complicating VWM disease, partic-
ularly in early onset cases, and consider the diagnosis of
VWM in children with both a leukodystrophy and
hypoglycaemia.
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